Cannabis and Gut Health

Key Takeaways

• In randomized trials of Crohn's disease and ulcerative colitis, cannabis improved pain, appetite, and quality of life while endoscopic scores and inflammatory markers did not separate from placebo [3, 4].
• Two pooled analyses, the larger covering eight randomized trials, agree that inflammatory markers and endoscopic activity do not change, while patient-reported symptoms improve [5, 6].
• Feeling better is not evidence that intestinal inflammation is under control, which is why cannabis does not substitute for prescribed IBD therapy.
• Evidence in irritable bowel syndrome is thinner. Its main placebo-controlled trial, 32 women using a 50 mg CBD gum on demand, found no group-level difference in pain scores [7].
• Cannabinoid hyperemesis syndrome is a documented consequence of chronic heavy use, and stopping cannabis is the only established treatment [9, 10].

---

A great many people with Crohn's disease, ulcerative colitis, or irritable bowel syndrome use cannabis for their symptoms, and a great many of them say it helps. Those reports come from enough patients, and hold up consistently enough, that waving them away makes little sense. On this narrow point the trials agree with the patients.

The trials complicate things elsewhere, in what that improvement actually signifies. Researchers studying inflammatory bowel disease track two separate things: how the patient feels, and what the inflammation is doing. In the cannabis trials those two measures came apart. Understanding why is the difference between using cannabis sensibly alongside treatment and using it in a way that lets serious disease advance unnoticed.

Why the Gut Responds to Cannabinoids at All

The endocannabinoid system runs throughout the digestive tract. CB1 receptors sit on the enteric and sensory nerves governing motility, secretion, and the perception of pain, while CB2 receptors appear more heavily on immune cells and connect to inflammatory signaling [1]. That layout explains why cannabinoids became a research question in gastroenterology at all. A compound class acting on both nerve signaling and immune activity in the gut is a reasonable thing to test against diseases defined by pain, disordered motility, and inflammation.

Plausibility is where investigation starts. Gastroenterology has a long record of interventions with elegant mechanisms that went on to fail in trials, and cannabinoids get held to the same standard as anything else. Receptors in the right place justify running a study without predicting how it ends.

What the Crohn's and Colitis Trials Found

The most cited study is a small placebo-controlled trial from 2013. Twenty-one patients with active Crohn's disease, none of whom had responded to steroids, immunomodulators, or anti-TNF therapy, were randomized to cannabis cigarettes containing 115 mg of THC twice daily or to placebo cigarettes made from THC-extracted flowers. Over eight weeks, ten of eleven patients on cannabis showed a clinical response against four of ten on placebo, a statistically significant difference. Complete remission occurred in five of eleven versus one of ten, but across twenty-one patients that gap missed significance, and remission was the trial's primary endpoint. Three patients came off steroid dependency [2].

That trial is a reason to run larger ones. The larger ones arrived, and added a detail that reframes the picture.

In 2021 the same group gave an oral CBD-rich cannabis oil to 56 patients with Crohn's disease over eight weeks. Disease activity improved, and quality of life rose from 74 to 91 against 75 on placebo. The simple endoscopic score showed no difference between groups, and C-reactive protein and fecal calprotectin, the two standard inflammatory markers, were unchanged [3].

A parallel trial in ulcerative colitis that year gave THC-rich cannabis cigarettes to 32 patients. Disease activity fell further on cannabis than on placebo, and quality of life improved substantially. The Mayo endoscopic score, which records what the camera sees on the colon wall, did not separate the groups [4].

A 2021 systematic review pooled the randomized evidence. Across five trials and 146 randomized adults, cannabinoids did not induce clinical remission, with a risk ratio of 1.56 and a confidence interval from 0.99 to 2.46, a range that includes no effect at all. Inflammatory biomarkers showed nothing. Abdominal pain, well-being, nausea, diarrhea, appetite, and quality of life all improved. Risk of bias across the included studies was rated moderate [5].

A 2025 meta-analysis widened the pool to eight randomized trials. Clinical disease activity improved in Crohn's disease, and quality of life improved in both diseases, while endoscopic disease activity and inflammatory markers showed no difference. Reduced disease activity and induced remission are different endpoints, so the two analyses are not in conflict on that point, and on inflammation they agree outright. The included trials varied a great deal among themselves, which leaves the pooled symptom estimates imprecise even where their direction is consistent [6].

Two Scorecards, One Patient

Inflammatory bowel disease gets scored two ways. One scorecard records the patient's experience: pain, stool frequency, energy, appetite, sleep, quality of life. The other records what is happening to the tissue, meaning what an endoscope sees on the bowel wall, how much calprotectin turns up in stool, what C-reactive protein reads in blood. For most treatments that work, the two move together. In the cannabis trials they came apart.

The distinction resembles a car's dashboard warning light and the engine behind it. Both report something true, and a driver experiences mostly the dashboard. A mechanic who checks only the dashboard will miss the thing that eventually strands the car.

One qualification keeps this honest. The trials did not demonstrate that cannabis fails to reduce inflammation. They failed to detect a reduction, across studies of a few dozen patients each over eight weeks. Small, short studies miss real effects routinely, and an undetected effect is weaker evidence than a disproved one. What the trials establish is that nobody has yet shown the anti-inflammatory benefit, and until someone does, symptom improvement cannot be read as a sign the disease is controlled.

The gap carries a specific danger in inflammatory bowel disease, where inflammation can keep damaging tissue while a patient feels well. Cutting back a prescribed therapy because cannabis has made things feel better is the failure this evidence warns against. The same structure appears elsewhere in cannabis medicine: in cancer care, cannabis-based drugs have an established role against chemotherapy-induced nausea while remaining unproven against tumors, a distinction covered in Cannabis and Cancer.

Where Irritable Bowel Syndrome Stands

Irritable bowel syndrome involves altered visceral sensation, disturbed motility, stress sensitivity, and amplified gut-brain signaling, all of which the endocannabinoid system touches [1]. Direct human evidence is far thinner here than in IBD.

The main placebo-controlled study enrolled 32 women with IBS and supplied a chewing gum containing 50 mg of CBD, used on demand up to six times daily, in a crossover design. Pain scores showed no statistically significant difference between CBD and placebo at the group level. Two features of the trial limit what that null result rules out: variation between individuals ran very high, and participants used far fewer gums than the design anticipated, so some received little CBD at all [7].

IBS is also unusually hard to study. Placebo response runs high, symptoms fluctuate on their own, and several distinct symptom patterns sit under one label. A small trial in that setting can miss a real effect as easily as it can correctly find nothing.

Signals exist elsewhere, though the largest of them did not hold. Olorinab, a molecule built to act on the CB2 receptor and to stay outside the brain, was tested against placebo in 273 patients with constipation-predominant or diarrhea-predominant IBS, at three doses over twelve weeks. No dose beat placebo on average abdominal pain, the primary endpoint. A prespecified subgroup with more severe pain at baseline did improve on the highest dose, a finding that invites a follow-up study and does not stand in for the endpoint that missed [8].

That null result carries more weight than the small cannabis trials do. The compound was a single molecule of known identity, the dose was fixed and supervised, and the sample was several times larger than any cannabis trial described here. When a study built that carefully finds nothing, the thinness of the IBS evidence stops looking like a sample-size problem alone.

Cannabinoid Hyperemesis Syndrome

The same plant used to control nausea can, under chronic heavy exposure, produce a syndrome of severe recurrent vomiting. Cannabinoid hyperemesis syndrome is recognized in gastroenterology and emergency medicine, and it is the most consequential safety issue in this area.

A frequently cited case series screened 1,571 patients with recurrent vomiting at one institution over five years and identified 98 meeting criteria. All were under 50. Among those with duration data, 68% had used cannabis for more than two years before symptoms began, and 95% of those with frequency data used more than once weekly. Abdominal pain affected 86%. Hot bathing was documented in 57 patients, of whom 52 reported that hot showers or baths relieved symptoms [9].

That series is retrospective and single-institution, and follow-up existed for only 10 of the 98 patients, so its recovery figures rest on a small subset. Within it, seven stopped using cannabis and six of those seven saw complete resolution [9].

The American Gastroenterological Association's 2024 clinical practice update puts cessation at the center of management. Supportive care during an acute episode can include fluids, electrolyte correction, and specific antiemetic approaches, but the evidence behind those measures is limited, and none resolves the syndrome [10].

Two ideas in circulation need correcting. The first holds that the syndrome is too rare to weigh in a decision. A cross-sectional study of roughly 806 million United States emergency department visits found hyperemesis-coded visits rising from 4.4 per 100,000 in 2016 to 22.3 per 100,000 in 2022, after a peak of 33.1 in the second quarter of 2020 [11]. Those counts come from administrative codes and not from clinical diagnoses, and coding for cyclic vomiting without a cannabis code fell across the same window, from 300 to 186 per 100,000, so some of the rise is cases moving between categories. Even the low end of that range is not rare. The second idea holds that rotating strains, switching to lower-THC products, or taking short tolerance breaks manages the syndrome. Nothing in the clinical literature supports it, and current guidance points to cessation [10]. The trap is that cannabis relieves nausea acutely, so patients often increase their use to control the vomiting, sustaining the very thing causing it.

What Separates a Careful Attempt From a Reckless One

Someone who has decided to try cannabis for gut symptoms can do it in a way that leaves the situation readable, or in a way that does not.

Keep prescribed therapy in place. Every trial showing symptom improvement studied patients who stayed on their existing treatment, and none tested cannabis as a replacement. Tell the gastroenterologist, because a clinician who does not know cannabis is involved cannot tell whether a change in symptoms reflects the disease, the drug, or the cannabis.

Change one thing at a time and allow eight weeks to read the result, the length of the trials that found benefit. Track the objective measures alongside how you feel, since calprotectin, C-reactive protein, and scheduled endoscopy are exactly the measures that did not separate from placebo in those trials. Decide in advance what would count as failure, and stop outright if cyclic vomiting appears, if hot showers become the thing that helps, or if controlling nausea starts to require using more.

Route changes exposure substantially. Inhaled cannabis peaks in the blood within minutes and clears fairly quickly, letting a person feel an effect and adjust, though how much gets absorbed varies with depth and duration of inhalation, so two people using the same product can take in very different amounts [12]. Oral products absorb slowly and erratically, and first-pass metabolism in the liver converts a large share of THC into a metabolite that is itself active, so the same dose can land differently depending on what else is in the stomach [12]. For someone whose gut motility is already unpredictable, that variability compounds.

None of this amounts to a dose. Products vary too much in composition for a number to carry across them, and no trial has established a therapeutic dose in IBD or IBS.

The Bottom Line

The evidence supports a narrow claim and refuses a broad one. Cannabis can improve pain, appetite, and quality of life for some people with inflammatory bowel disease, and those improvements were real, measured, and repeated across trials. No trial has shown an effect on the inflammation driving the disease. In irritable bowel syndrome even the symptom evidence remains unsettled, and chronic heavy use carries a hyperemesis risk that consumer coverage tends to soften.

Alongside prescribed treatment, and discussed openly with the clinician managing the disease, cannabis has a defensible place in symptom management. Instead of it, cannabis exposes a person to the progression of a disease they can no longer feel.

The fuller clinical picture, including trial design, the gut-brain axis, and where the research goes next, is set out in the companion Hytiva Research article, Cannabis and Gastrointestinal Health.

Frequently Asked Questions

Does cannabis reduce inflammation in Crohn's disease or ulcerative colitis? No trial has shown that it does. Randomized studies found improvement in symptoms and quality of life without a matching separation from placebo on endoscopic scores, C-reactive protein, or fecal calprotectin [3, 4, 5, 6]. Those studies failed to detect an effect, which is not the same as proving none exists, but anti-inflammatory benefit cannot be claimed today.

Can cannabis replace my IBD medication? No. Every trial showing benefit studied patients who stayed on their prescribed therapy, and inflammation can keep damaging tissue while symptoms feel controlled.

Does cannabis help IBS? The evidence is limited and inconclusive. The main placebo-controlled trial found no group-level benefit from a 50 mg CBD gum, though high variability between individuals and lower-than-expected use limit what it rules out [7].

What is cannabinoid hyperemesis syndrome? Recurrent severe vomiting, nausea, and abdominal pain tied to chronic heavy cannabis use, often with relief from hot showers or baths [9]. Stopping cannabis is the only established treatment [10].

Will switching to a lower-THC product prevent hyperemesis syndrome? No clinical evidence supports that. Current gastroenterology guidance points to cessation [10].

References

• [^1]: Camilleri M, Zheng T. Cannabinoids and the Gastrointestinal Tract. Clin Gastroenterol Hepatol. 2023;21(13):3217-3229. https://pubmed.ncbi.nlm.nih.gov/37678488/
• [^2]: Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.e1. https://pubmed.ncbi.nlm.nih.gov/23648372/
• [^3]: Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial. J Crohns Colitis. 2021;15(11):1799-1806. https://pubmed.ncbi.nlm.nih.gov/33858011/
• [^4]: Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS One. 2021;16(2):e0246871. https://pubmed.ncbi.nlm.nih.gov/33571293/
• [^5]: Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH. A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies? J Clin Gastroenterol. 2021;55(9):798-809. https://pubmed.ncbi.nlm.nih.gov/32675631/
• [^6]: Kang H, Schmoyer CJ, Weiss A, Lewis JD. Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2025;31(2):450-460. https://pubmed.ncbi.nlm.nih.gov/39197096/
• [^7]: van Orten-Luiten ACB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2022;7(4):436-444. https://pubmed.ncbi.nlm.nih.gov/33998882/
• [^8]: Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Tack J. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE). Neurogastroenterol Motil. 2023;35(5):e14539. https://pubmed.ncbi.nlm.nih.gov/36740814/
• [^9]: Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114-119. https://pubmed.ncbi.nlm.nih.gov/22305024/
• [^10]: Rubio-Tapia A, McCallum R, Camilleri M. AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary. Gastroenterology. 2024;166(5):930-934.e1. https://pubmed.ncbi.nlm.nih.gov/38456869/
• [^11]: Swartz JA, Franceschini D. Cannabinoid Hyperemesis Syndrome, 2016 to 2022. JAMA Netw Open. 2025;8(11):e2545310. https://pubmed.ncbi.nlm.nih.gov/41284293/
• [^12]: Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804. https://pubmed.ncbi.nlm.nih.gov/17712819/